Cargando…

Fluvoxamine for the treatment of COVID-19

Detalles Bibliográficos
Autores principales:	Kim, Hyun, Manzi, Shannon, Gonzelez-Heydrich, Joseph, Picker, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846602/ https://www.ncbi.nlm.nih.gov/pubmed/35180410 http://dx.doi.org/10.1016/S2214-109X(22)00003-1

Ejemplares similares

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Why we should not recommend or offer fluvoxamine to COVID-19 patients?
por: Trkulja, Vladimir
Publicado: (2022)

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023)

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
por: Khani, Elnaz, et al.
Publicado: (2022)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
por: Mahdi, Mohamed, et al.
Publicado: (2022)

Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Fluvoxamine in the treatment of anxiety disorders
por: Irons, Jane
Publicado: (2005)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Antipsychotics and COVID-19: the debate goes on – Authors' reply
por: De Picker, Livia, et al.
Publicado: (2021)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
por: Hashimoto, Kenji
Publicado: (2023)

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
por: Seftel, David, et al.
Publicado: (2021)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

Mechanisms of action of fluvoxamine for COVID-19: a historical review
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials
por: Guo, Christina M., et al.
Publicado: (2022)

Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model
por: Mills, Fergal P., et al.
Publicado: (2023)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2022)

Fluvoxamine pour les patients atteints de COVID-19 non hospitalisés
por: Wu, Peter E., et al.
Publicado: (2022)

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
por: Sukhatme, Vikas P., et al.
Publicado: (2021)

Tolerability and safety of fluvoxamine and other antidepressants
por: Westenberg, HGM, et al.
Publicado: (2006)

Fluvoxamine alleviates paclitaxel-induced neurotoxicity
por: Tanimukai, Hitoshi, et al.
Publicado: (2015)

Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
por: Seo, Hyeonji, et al.
Publicado: (2022)

Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study
por: Pineda, Estela, et al.
Publicado: (2022)

Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women
por: Oishi, Akira, et al.
Publicado: (2007)

Emergence of kleptomania during treatment for obsessive compulsive disorder with fluvoxamine
por: Gupta, Parveen Rani
Publicado: (2014)

Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?
por: Marčec, Robert, et al.
Publicado: (2021)

Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up
por: Bramante, Carolyn T., et al.
Publicado: (2022)

Could Fluvoxamine Dose De-escalation Increase Treatment Compliance Without Sacrificing Efficacy in COVID-19 Patients?
por: Marcec, Robert, et al.
Publicado: (2022)

Limits of Monoclonal Antibody Treatment in Pregnant Women Complicated with COVID-19 Due to The Omicron Variant
por: Cha, Hyun-Hwa, et al.
Publicado: (2022)

An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment
por: Arishi, Naif A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e8ukni1itnvjog8naa7usngp5k